JP2020511140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511140A5 JP2020511140A5 JP2019550815A JP2019550815A JP2020511140A5 JP 2020511140 A5 JP2020511140 A5 JP 2020511140A5 JP 2019550815 A JP2019550815 A JP 2019550815A JP 2019550815 A JP2019550815 A JP 2019550815A JP 2020511140 A5 JP2020511140 A5 JP 2020511140A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- seq
- region
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100023804 Coagulation factor VII Human genes 0.000 claims 21
- 108010023321 Factor VII Proteins 0.000 claims 21
- 229940012413 factor vii Drugs 0.000 claims 21
- 108060003951 Immunoglobulin Proteins 0.000 claims 20
- 102000018358 immunoglobulin Human genes 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 239000013604 expression vector Substances 0.000 claims 8
- 108010000499 Thromboplastin Proteins 0.000 claims 7
- 102000002262 Thromboplastin Human genes 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000035772 mutation Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 239000003504 photosensitizing agent Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940072221 immunoglobulins Drugs 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471045P | 2017-03-14 | 2017-03-14 | |
| US62/471,045 | 2017-03-14 | ||
| US201762576278P | 2017-10-24 | 2017-10-24 | |
| US62/576,278 | 2017-10-24 | ||
| US201862623269P | 2018-01-29 | 2018-01-29 | |
| US62/623,269 | 2018-01-29 | ||
| PCT/US2018/022443 WO2018170134A1 (en) | 2017-03-14 | 2018-03-14 | Methods and compositions related to a tissue factor-targeting igg3 immunoconjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511140A JP2020511140A (ja) | 2020-04-16 |
| JP2020511140A5 true JP2020511140A5 (https=) | 2021-04-30 |
| JP7155144B2 JP7155144B2 (ja) | 2022-10-18 |
Family
ID=63523847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550815A Active JP7155144B2 (ja) | 2017-03-14 | 2018-03-14 | 組織因子標的化ＩｇＧ３免疫複合体に関連する方法及び組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11872194B2 (https=) |
| EP (1) | EP3595707A4 (https=) |
| JP (1) | JP7155144B2 (https=) |
| CN (1) | CN110520152A (https=) |
| AU (1) | AU2018235945A1 (https=) |
| CA (1) | CA3056396A1 (https=) |
| MA (1) | MA47786A (https=) |
| WO (1) | WO2018170134A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3687555A4 (en) * | 2017-09-27 | 2021-07-21 | Ohio State Innovation Foundation | CAR-NK CELL THERAPY AND CAR-T TISSUE FACTOR TARGETING |
| WO2022106648A1 (en) | 2020-11-20 | 2022-05-27 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | Inhibitors of the tissue factor-protease activated receptor 2 (tf-par2) signaling pathway for use in the treatment or prevention of heart failure (hf) and associated or resulting diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649151A (en) | 1982-09-27 | 1987-03-10 | Health Research, Inc. | Drugs comprising porphyrins |
| US5095030A (en) | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US4920143A (en) | 1987-04-23 | 1990-04-24 | University Of British Columbia | Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents |
| US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US4883790A (en) | 1987-01-20 | 1989-11-28 | University Of British Columbia | Wavelength-specific cytotoxic agents |
| US5190966A (en) | 1988-07-06 | 1993-03-02 | Health Research, Inc. | Purified hematoporphyrin dimers and trimers useful in photodynamic therapy |
| US4968715A (en) | 1988-07-06 | 1990-11-06 | Health Research, Inc. | Use of purified hematoporphyrin trimers in photodynamic therapy |
| US5093349A (en) | 1988-07-20 | 1992-03-03 | Health Research Inc. | Photosensitizing agents |
| US5198460A (en) | 1988-07-20 | 1993-03-30 | Health Research Inc. | Pyropheophorbides and their use in photodynamic therapy |
| US5002962A (en) | 1988-07-20 | 1991-03-26 | Health Research, Inc. | Photosensitizing agents |
| US5173504A (en) | 1989-04-21 | 1992-12-22 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5171741A (en) | 1989-04-21 | 1992-12-15 | Health Research, Inc. | Bacteriochlorophyll-a derivatives useful in photodynamic therapy |
| US5079262A (en) | 1989-07-28 | 1992-01-07 | Queen's University At Kingston | Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid |
| US5166197A (en) | 1990-07-17 | 1992-11-24 | Kenney Malcolm E | Phthalocyanine photosensitizers for photodynamic therapy |
| US5244914A (en) | 1992-04-27 | 1993-09-14 | American Cyanamid Company | Stable porfimer sodium compositions and methods for their manufacture |
| US6924359B1 (en) * | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
| DK1198479T3 (da) | 1999-07-01 | 2008-10-13 | Univ Yale | Neovaskulamålrettet immunkonjugat |
| US6443976B1 (en) | 1999-11-30 | 2002-09-03 | Akorn, Inc. | Methods for treating conditions and illnesses associated with abnormal vasculature |
| CA2408323C (en) | 2000-05-08 | 2012-06-12 | The University Of British Columbia | Drug delivery systems for photodynamic therapy |
| US20040110929A1 (en) * | 2002-07-12 | 2004-06-10 | Bjorn Soren E. | TF binding compound |
| PT1624891E (pt) * | 2003-05-06 | 2010-01-05 | Syntonix Pharmaceuticals Inc | Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2006020979A2 (en) * | 2004-08-13 | 2006-02-23 | Yale University | Factor vii conjugates for selectively treating neovascularization disorders |
| SG10201505217WA (en) | 2010-07-09 | 2015-08-28 | Biogen Hemophilia Inc | Chimeric clotting factors |
| CN104774269B (zh) * | 2013-08-16 | 2016-02-24 | 安源生物科技(上海)有限公司 | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 |
| BR112018001148A2 (pt) * | 2015-08-06 | 2018-09-11 | Glycotope Gmbh | heterômeros compreendendo proteínas de fusão com domínios de anticorpos |
| EP3442554A4 (en) * | 2016-04-14 | 2019-12-04 | Iconic Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATING DISEASES RELATED TO NEOVASCULARIZATION |
-
2018
- 2018-03-14 CA CA3056396A patent/CA3056396A1/en active Pending
- 2018-03-14 WO PCT/US2018/022443 patent/WO2018170134A1/en not_active Ceased
- 2018-03-14 AU AU2018235945A patent/AU2018235945A1/en not_active Abandoned
- 2018-03-14 US US16/494,177 patent/US11872194B2/en active Active
- 2018-03-14 CN CN201880018514.6A patent/CN110520152A/zh active Pending
- 2018-03-14 EP EP18766917.1A patent/EP3595707A4/en active Pending
- 2018-03-14 MA MA047786A patent/MA47786A/fr unknown
- 2018-03-14 JP JP2019550815A patent/JP7155144B2/ja active Active
-
2023
- 2023-12-05 US US18/529,638 patent/US20240123042A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds | |
| Hou et al. | Therapeutic protein PEPylation: the helix of nonfouling synthetic polypeptides minimizes antidrug antibody generation | |
| RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| ES2199941T3 (es) | Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j. | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP7665600B2 (ja) | 抗腫瘍溶解性ウイルス抗原抗体およびその使用方法 | |
| CN103965363B (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2010511388A5 (https=) | ||
| JP2017531427A5 (https=) | ||
| CN110740754A (zh) | 一种抗间皮素抗体及其抗体药物缀合物 | |
| JP2008508864A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| JP2008542278A5 (https=) | ||
| JP2010533498A5 (https=) | ||
| JP2018502060A5 (https=) | ||
| JP2014039548A5 (https=) | ||
| JP2018510617A5 (https=) | ||
| JP2018506277A5 (https=) | ||
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| JP2014510519A5 (https=) | ||
| JP2021526377A5 (https=) | ||
| JP2017529870A5 (https=) | ||
| RU2013134983A (ru) | Рекомбинантные антитела против фактора роста эндотелия сосудов (vegf), полученные посредством мутагенеза вариабельной области | |
| CN112839952A (zh) | 包含基于pd-1的嵌合蛋白的组合疗法 | |
| JP2017518318A5 (https=) |